AAAAAA
Results: 1-25/48
Authors:
Wierzbicki, AS
Citation: As. Wierzbicki, Is a statin a statin?, INT J CL PR, 55(2), 2001, pp. 79-80
Authors:
Mukherji, M
Kershaw, NJ
MacKinnon, CH
Clifton, IJ
Wierzbicki, AS
Schofield, CJ
Lloyd, MD
Citation: M. Mukherji et al., 'Chemical co-substrate rescue' of phytanoyl-CoA 2-hydroxylase mutants causing Refsum's Disease, CHEM COMMUN, (11), 2001, pp. 972-973
Authors:
Mukherji, M
Chien, W
Kershaw, NJ
Clifton, IJ
Schofield, CJ
Wierzbicki, AS
Lloyd, MD
Citation: M. Mukherji et al., Structure-function analysis of phytanoyl-CoA 2-hydroxylase mutations causing Refsum's disease, HUM MOL GEN, 10(18), 2001, pp. 1971-1982
Authors:
Wierzbicki, AS
Citation: As. Wierzbicki, Lipid-lowering drugs in lupus: an unexplored therapeutic intervention, LUPUS, 10(3), 2001, pp. 233-236
Authors:
Kershaw, NJ
Mukherji, M
MacKinnon, CH
Claridge, TDW
Odell, B
Wierzbicki, AS
Lloyd, MD
Schofield, CJ
Citation: Nj. Kershaw et al., Studies on phytanoyl-CoA 2-hydroxylase and synthesis of phytanoyl-coenzymeA, BIOORG MED, 11(18), 2001, pp. 2545-2548
Authors:
Hardman, TC
Wierzbicki, AS
Citation: Tc. Hardman et As. Wierzbicki, Erythrocyte sodium-lithium countertransport in African American women, J HUM HYPER, 15(7), 2001, pp. 505-506
Authors:
Wierzbicki, AS
Hardman, TC
Cheung, J
Patel, M
Smallberger, S
Lumb, PJ
Lant, AF
Citation: As. Wierzbicki et al., Relation between sodium-lithium countertransport and hypertriglyceridemia in type V hyperlipidemia, AM J HYPERT, 14(1), 2001, pp. 32-37
Authors:
Wierzbicki, AS
Citation: As. Wierzbicki, Synthetic statins: More data on newer lipid-lowering agents, CURR MED R, 17(1), 2001, pp. 74-77
Authors:
Mikhaildis, DP
Wierzbicki, AS
Reynolds, TM
Citation: Dp. Mikhaildis et al., Is a mechanical or a metabolic approach superior in the treatment of coronary disease? Results of the atorvastatin versus revascularization (AVERT) trial, EUR HEART J, 22(11), 2001, pp. 972-972
Authors:
Wierzbicki, AS
Watts, GF
Lynas, J
Winder, AF
Wray, R
Citation: As. Wierzbicki et al., Very low-density lipoprotein apolipoprotein B-100 turnover in glycogen storage disease type Ia (von Gierke disease), J INH MET D, 24(5), 2001, pp. 527-534
Authors:
Wierzbicki, AS
Crook, MA
Reynolds, TM
Mikhailidis, DP
Citation: As. Wierzbicki et al., Measurement of atherosclerosis progression, LANCET, 358(9278), 2001, pp. 329-330
Authors:
Wierzbicki, AS
Reynolds, TM
Citation: As. Wierzbicki et Tm. Reynolds, Statins and fractures, LANCET, 357(9271), 2001, pp. 1887-1887
Authors:
Wierzbicki, AS
Mikhaildis, DP
Reynolds, TR
Citation: As. Wierzbicki et al., Atorvastatin for acute coronary syndromes, J AM MED A, 286(5), 2001, pp. 532-533
Authors:
Wierzbicki, AS
Lumb, PJ
Chik, G
Crook, MA
Citation: As. Wierzbicki et al., Fibrinogen response with simvastatin versus atorvastatin in familial hypercholesterolemia, AM J CARD, 87(3), 2001, pp. 338
Authors:
Mangoni, AA
Ouldred, E
Swif, CG
Jackson, SHD
Draper, RP
Sherwood, RA
Lambert-Hammill, M
Wierzbicki, AS
Citation: Aa. Mangoni et al., Vascular and blood pressure effects of folic acid in older patients with cardiovascular disease, J AM GER SO, 49(7), 2001, pp. 1003-1004
Authors:
Wierzbicki, AS
Citation: As. Wierzbicki, The implications of the National Service Framework for coronary heart disease, J R SOC P H, 120(3), 2000, pp. 143-145
Authors:
Wierzbicki, AS
Citation: As. Wierzbicki, Does diet have a role in the treatment of hyperlipidaemia?, INT J CL PR, 54(2), 2000, pp. 72-73
Authors:
Wierzbicki, AS
Reynolds, TM
Citation: As. Wierzbicki et Tm. Reynolds, Cost effectiveness of statins, HEART, 83(6), 2000, pp. 713-714
Authors:
Wierzbicki, AS
Lambert-Hammill, M
Junadi, E
Lumb, PJ
Crook, MA
Citation: As. Wierzbicki et al., Differing relationships of methylene tetrahydrofolate reductase genotypes with cardiovascular risk in familiar and polygenic hypercholesterolaemia, J CARD RISK, 7(6), 2000, pp. 431-434
Authors:
Wierzbicki, AS
Reynolds, TM
Gill, K
Alg, S
Crook, MA
Citation: As. Wierzbicki et al., A comparison of algorithms for initiation of lipid lowering therapy in primary prevention of coronary heart disease, J CARD RISK, 7(1), 2000, pp. 63-71
Authors:
Wierzbicki, AS
Mitchell, J
Lambert-Hammill, M
Hancock, M
Greenwood, J
Sidey, MC
de Belleroche, J
Gibberd, FB
Citation: As. Wierzbicki et al., Identification of genetic heterogeneity in Refsum's disease, EUR J HUM G, 8(8), 2000, pp. 649-651
Authors:
Wierzbicki, AS
Citation: As. Wierzbicki, Lipids, cardiovascular disease and atherosclerosis in systemic lupus erythematosus, LUPUS, 9(3), 2000, pp. 194-201
Authors:
Reynolds, TM
Wierzbicki, AS
Citation: Tm. Reynolds et As. Wierzbicki, Survival and reduction in mortality from breast cancer - Diagnostic practice in the United States is different, BR MED J, 321(7274), 2000, pp. 1471-1471
Survival and reduction in mortality from breast cancer - Improvements in survival may be an illusion
Authors:
Reynolds, TM
Wierzbicki, AS
Citation: Tm. Reynolds et As. Wierzbicki, Survival and reduction in mortality from breast cancer - Improvements in survival may be an illusion, BR MED J, 321(7274), 2000, pp. 1471-1471
Authors:
Wierzbicki, AS
Reynolds, TM
Citation: As. Wierzbicki et Tm. Reynolds, National service framework's financial implications are huge, BR MED J, 321(7262), 2000, pp. 705-705